-
Subject Areas on Research
-
"Me-too" products--friend or foe?
-
A clinical decision and economic analysis model of cancer pain management.
-
A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting.
-
A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.
-
A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.
-
A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.
-
A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
-
ALSUntangled No. 34: GM604.
-
ALSUntangled No. 47: RT001.
-
Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?
-
Adverse Change in Employment Status After Acute Myocardial Infarction: Analysis From the TRANSLATE-ACS Study.
-
Aerosolized ribavirin: the most expensive drug for pneumonia.
-
Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time.
-
Albumin industry launches global promotion.
-
American Society of Clinical Oncology guidance statement: the cost of cancer care.
-
An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation.
-
An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection.
-
Anticoagulants in pregnancy.
-
Appropriateness of medication prescribing in ambulatory elderly patients.
-
Are free anti-tuberculosis drugs enough? An empirical study from three cities in China.
-
Assessing the clinical and economic burden of coronary artery disease: 1986-1998.
-
Association Between Exercise Frequency and Health Care Costs Among Employees at a Large University and Academic Medical Center.
-
Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
-
Cancer treatment cost in the United States: has the burden shifted over time?
-
Cardiovascular Drug Pricing: Less Innovation for More Access?
-
Clinical Trial Design in Juvenile Idiopathic Arthritis.
-
Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options
-
Commercial features of placebo and therapeutic efficacy.
-
Comparative effectiveness: insights on treatment options for open-angle glaucoma.
-
Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial.
-
Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
-
Conversations in cardiology: bridging antiplatelet therapy before surgery.
-
Copay Assistance for Expensive Drugs: A Helping Hand That Raises Costs.
-
Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS Trial.
-
Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials.
-
Cost effectiveness analysis of early zidovudine treatment of HIV infected patients.
-
Cost effectiveness of abciximab during routine medical practice.
-
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
-
Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
-
Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options.
-
Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
-
Cost-Effectiveness Analysis of Qsymia for Weight Loss.
-
Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
-
Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.
-
Cost-effective reduction of neuromuscular-blocking drug expenditures.
-
Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
-
Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD.
-
Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy.
-
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
-
Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
-
Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison.
-
Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.
-
Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
-
Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia.
-
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
-
Cost-related nonadherence in the Medicare program: the impact of Part D.
-
Costs associated with febrile neutropenia in the US.
-
Cryoprecipitate therapy.
-
DRIVE it home: making the case for prospective economic data collection in randomized clinical trials.
-
Differential pricing of pharmaceuticals in the internet age.
-
Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
-
Does generic entry always increase consumer welfare?
-
Drug Development. Are trade secrets delaying biosimilars?
-
Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome).
-
Economic analysis in eye disease.
-
Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.
-
Economic analysis of influenza vaccination and antiviral treatment for healthy working adults.
-
Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
-
Economic burden of heart failure in the elderly.
-
Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy.
-
Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer.
-
Economic return of clinical trials performed under the pediatric exclusivity program.
-
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics.
-
Economics of low-molecular weight heparins.
-
Economics of new oncology drug development.
-
Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial.
-
Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.
-
Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors.
-
Essentials of prescribing in the era of the Medicare Prescription Drug Improvement and Modernization Act.
-
Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?
-
Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need.
-
FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression.
-
Generic clopidogrel: time to substitute?
-
Global health and university patents.
-
Haloperidol for postoperative nausea and vomiting: are we reinventing the wheel?
-
Health agencies end in-fighting on malaria.
-
Health care cost growth among the privately insured.
-
Health care costs.
-
Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis.
-
Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV.
-
Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs.
-
Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer.
-
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
-
Implications of cost in treatment selection for patients with coronary heart disease.
-
Improving rational use of ACTs through diagnosis-dependent subsidies: Evidence from a cluster-randomized controlled trial in western Kenya.
-
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
-
In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival.
-
Incremental cost-effectiveness of evidence-based non-surgical weight loss strategies.
-
Ingredients of successful interventions to improve medication adherence.
-
Inpatient Antimicrobial Stewardship in Pediatrics: A Systematic Review.
-
International price comparisons for novel and follow-on drugs.
-
Isoniazid preventive therapy in medium-incidence settings: the price is right.
-
Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease.
-
Late treatment of HIV infection--is it better?
-
Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery.
-
Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
-
Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
-
Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
-
Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
-
Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
-
Medical Marijuana Laws May Be Associated With A Decline In The Number Of Prescriptions For Medicaid Enrollees.
-
Medication adherence: a call for action.
-
Modeling the Budgetary Impact of Payer Utilization Management Strategies: An Adapted Framework Based on Lessons Learned.
-
Myelodysplastic syndromes.
-
Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?
-
Obstacles and proposed solutions to effective antiretroviral therapy in resource-limited settings.
-
Optimising outcomes: socioeconomic perspective.
-
Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?
-
Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study.
-
Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.
-
Patient experience and attitudes toward addressing the cost of breast cancer care.
-
Patient-Physician Communication on Medication Cost during Glaucoma Visits.
-
Payment Reform, Medication Use, and Costs: Can We Afford to Leave Out Drugs?
-
Perspectives on the Costs of Cancer Care: A Survey of the American Society of Breast Surgeons.
-
Perverse incentives in the Medicare prescription drug benefit.
-
Pharmaceutical prices, quantities and innovation. Comparing Japan with the US.
-
Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction.
-
Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.
-
Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2).
-
Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
-
Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment.
-
Potential bias in medication adherence studies of prevalent users.
-
Potential impact of pharmaceutical industry rebates on medication adherence.
-
Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials.
-
Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.
-
Prevalence and Cost Analysis of Chronic Pain After Hernia Repair: A Potential Alternative Approach With Neurostimulation.
-
Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care.
-
Price differentiation and transparency in the global pharmaceutical marketplace.
-
Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
-
Programs promoting timely sequential antimicrobial therapy: an American perspective.
-
Public Health Impact of the Centers for Medicare and Medicaid Services Decision on Pass-Through Add-On Payments for Drug-Coated Balloons: A Call to Action.
-
Quantifying the utility of taking pills for cardiovascular prevention.
-
Rational use of medications: if Canada can't do it ...
-
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
-
Rationing HIV medications: what do patients and the public think about allocation policies?
-
Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
-
Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.
-
Repairing the broken market for antibiotic innovation.
-
Repeat experience with the doughnut hole in Medicare Part D: when the doughnut hole becomes a tunnel.
-
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
-
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
-
Rocephin--the thin end of the wedge.
-
Should the patent system for new medicines be abolished?
-
Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.
-
Steroid treatment for myasthenia gravis: steroids have an important role.
-
Study on Incentives for Glaucoma Medication Adherence (SIGMA): study protocol for a randomized controlled trial to increase glaucoma medication adherence using value pricing.
-
Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis.
-
Subsidising artemisinin-based combination therapy in the private retail sector.
-
Successful use of education and cost-based feedback strategies to reduce physician utilization of low-osmolality contrast agents in the cardiac catheterization laboratory.
-
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
-
The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
-
The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients.
-
The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001.
-
The cost of assisted outpatient treatment: can it save states money?
-
The cost of drug development.
-
The economic burden of anxiety disorders in the 1990s.
-
The economics of PCSK-9 inhibitors.
-
The economics of febrile neutropenia: implications for the use of colony-stimulating factors.
-
The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature.
-
The insurance effect on prescription drug expenditures among the elderly: findings from the 1997 Medical Expenditure Panel Survey.
-
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
-
The state and consequences of dermatology drug prices in the United States.
-
The successful implementation of pharmaceutical practice guidelines. Analysis of associated outcomes and cost savings. SWiPE Group. Systematic Withdrawal of Perioperative Expenses.
-
Tigecycline: a new glycylcycline antimicrobial.
-
Tuberculosis patient expenditure on drugs and tests in subsidised, public services in China: a descriptive study.
-
Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools.
-
Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study.
-
Value-based insurance design: quality improvement but no cost savings.
-
Variation in the cost of medications for the treatment of colorectal cancer.
-
What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial.
-
What is the role of combination drug therapy in the treatment of overactive bladder? ICI-RS 2014.
-
When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial--an overview. Efficacy and Safety of Subcutaneous in non-Q Wave Coronary Events.
-
Would greater transparency and uniformity of health care prices benefit poor patients?
-
Keywords of People
-
O'Connor, Christopher Michael,
Richard Sean Stack, M.D. Distinguished Professor,
Medicine, Clinical Pharmacology
-
Reed, Shelby Derene,
Professor in Population Health Sciences,
Duke Science & Society
-
Ridley, David Blaine,
Professor of the Practice of Business Adminstration,
Duke Science & Society